Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis
View/ Open
Impact
Scholar |
Other documents of the author: Martínez-Martín, Pablo; Rodríguez-Blázquez, Carmen; Paz, Silvia; Forjaz, Maria João; Frades-Payo, Belén; Cubo, Esther; De Pedro Cuesta, Jesús; Lizán, Luis; ELEP Group
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadata
Title
Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysisAuthor (s)
Date
2015Publisher
Public Library of ScienceISSN
1932-6203Bibliographic citation
Martinez-Martín P, Rodriguez-Blazquez C, Paz S, Forjaz MJ, Frades-Payo B, Cubo E, et al. (2015) Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PLoS ONE 10(12): e0145310. doi:10.1371/journal.pone.0145310Type
info:eu-repo/semantics/articlePublisher version
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145310Version
info:eu-repo/semantics/publishedVersionSubject
Abstract
Objective
To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period.
Materials and Methods
Data collected during ... [+]
Objective
To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period.
Materials and Methods
Data collected during 3-month, each year, for 4 years, from the ELEP study, included sociodemographic, clinical and use of resources information. Costs were calculated yearly, as mean 3-month costs/patient and updated to Spanish €, 2012. Mixed linear models were performed to analyze total, direct and indirect costs based on symptoms and HRQoL.
Results
One-hundred and seventy four patients were included. Mean (SD) age: 63 (11) years, mean (SD) disease duration: 8 (6) years. Ninety-three percent were HY I, II or III (mild or moderate disease). Forty-nine percent remained in the same stage during the study period. Clinical evaluation and HRQoL scales showed relatively slight changes over time, demonstrating a stable group overall. Mean (SD) PD total costs augmented 92.5%, from €2,082.17 (€2,889.86) in year 1 to €4,008.6 (€7,757.35) in year 4. Total, direct and indirect cost incremented 45.96%, 35.63%, and 69.69% for mild disease, respectively, whereas increased 166.52% for total, 55.68% for direct and 347.85% for indirect cost in patients with moderate PD. For severe patients, cost remained almost the same throughout the study. For each additional point in the SCOPA-Motor scale total costs increased €75.72 (p = 0.0174); for each additional point on SCOPA-Motor and the SCOPA-COG, direct costs incremented €49.21 (p = 0.0094) and €44.81 (p = 0.0404), respectively; and for each extra point on the pain scale, indirect costs increased €16.31 (p = 0.0228).
Conclusions
PD is an expensive disease in Spain. Disease progression and severity as well as motor and cognitive dysfunctions are major drivers of costs increments. Therapeutic measures aimed at controlling progression and symptoms could help contain disease expenses. [-]
Is part of
PLOS ONE Volumen: 10 Número: 12 Número de artículo: e0145310Rights
info:eu-repo/semantics/openAccess
This item appears in the folowing collection(s)
- MED_Articles [636]
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as © 2015 Martinez-Martín et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.